Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed or recurrent mild to moderate left-sided active ulcerative colitis
Mayo score of at least 4 but not greater than 10 points and a score of ≥ 2 for colonoscopy
Extent of colonic involvement and endoscopy subscore of Mayo score as confirmed by colonoscopy
The patient is compliant with Patient Daily Diary by having adequately responded to the questions on ≥5 of the most recent full 7 days before the Randomization Visit
Negative stool test at screening to rule out parasites and bacterial pathogens
You may not be if
Patients receiving \> 2g/day of oral 5-aminosalicylic acid (5-ASA) products, or receiving topical rectal 5-ASA \> 3g/week, within 7 days prior to screening
Severe/fulminant ulcerative colitis or toxic dilatation of the colon
Prior bowel resection surgery
Patients allergic to 5-ASA and derivative, any of the excipients, aspirin, or salicylates
Patients with one or more of the diseases: bacillary dysentery, amebic dysentery, chronic schistosomiasis, intestinal tuberculosis and Crohn's disease
Patients who are unable to fill in the Patient Daily Diary or follow data-capturing procedures
Clareo Health | An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase
